PA
IPXL

Perceptive Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

Perceptive Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed – – 226
2016
Q4 		$0 Buy
+1
New +$17 ﹤0.01% 236
2014
Q2 		– Sell
-5,962
Closed -$158K – 160
2014
Q1 		$158K Hold
5,962
– – 0.02% 112
2013
Q4 		$150K Buy
+5,962
New +$133K 0.02% 95

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Perceptive Advisors's IPXL Position: Q1 2017 in Review

Perceptive Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 1 share.

Perceptive Advisors first reported a position in IPXL in Q4 2013 and held it in 3 quarters. The position peaked at $158K in Q1 2014. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • Perceptive Advisors reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • Perceptive Advisors sold 1 Impax Laboratories, Inc. share in Q1 2017.
  • Perceptive Advisors first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 3 quarters.
  • Perceptive Advisors's Impax Laboratories, Inc. position peaked at $158K in Q1 2014.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.